Gene Therapy Vaccines in Acute Myeloid Leukemia: A Need for Clinical Evaluation

References

• Mathe, G., Amiel, M. J., Schwarzenberg, L., Schneider, M., Cattan, A., Schlumberger, J. R., Hayat, M. and De Vassal, F. (1969). Active immunotherapy for acute lymphoblastic leukemia. Lancet, 1, 697–699.
   PubMed Web of Science ®Google Scholar
• Powles, R. L., Crowther, D., Bateman, C. J. T., Beard, M. E., McElwain, T. J., Russell, J., Lister, T. A., Whitehouse, J. M., Wrigley, P. F., Pike, M., Alexander, P. and Fairley, G. H. (1973). Immunotherapy for acute myelogenous leukaemia. Br J Cancer, 28, 365–376.
   PubMed Web of Science ®Google Scholar
• Foon, K., Smalley, R. V., Riggs, C. W. and Gale, R. P. (1983). The Role of Immunotherapy in Acute Myelogenous Leukemia. Arch Intern Med, 143, 1726–1731.
   PubMed Web of Science ®Google Scholar
• Lowenberg, B., Downing, J. R. and Burnett, A. (1999). Acute myeloid leukemia. N Engl J Med, 341, 1051–1062.
   PubMed Web of Science ®Google Scholar
• Kourilsky, P. and Claverie, J. M. (1986). The peptidic self model: a hypothesis on the molecular nature of the immunological self. Ann Inst Pasteur Immunol, 137, 3–21.
   Google Scholar
• Boon, T., De Plaen, E., Lurquin, C., Van den Eynd, B., van der Bruggen, P., Traversari, C., Amar-Costesec, A. and Van Pel, A. (1992). Identification of tumour rejection antigens recognized by T lymphocytes. Cancer Surv, 13, 23–37.
   PubMedGoogle Scholar
• Campbell, M. J., Esserman, L., Byars, N. E., Allison, A. C. and Levy, R. (1989). Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor. Int Rev Immunol, 4, 251–270.
   PubMedGoogle Scholar
• Germain, R. N. and Margulies, D. H. (1993). The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol, 11, 403–450.
   PubMed Web of Science ®Google Scholar
• Bjorkman, P. J. and Parham, P. (1990). Structure, function, and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem, 59, 253–288.
   PubMed Web of Science ®Google Scholar
• Unanue, E. R. and Allen, P. M. (1987). The basis for the immunoregulatory role of macrophages and other accessory cells. Science, 236, 551–557.
   PubMed Web of Science ®Google Scholar
• Powis, S. J., Deverson, E. V., Coadwell, W. J., Ciruela, A., Huskisson, N. S., Smith, H., Butcher, G. W. and Howard, J. C. (1992). Effect of polymorphism of an MHC-linked transporter on the peptides assembled in a class I molecule. Nature, 357, 211–215.
   PubMed Web of Science ®Google Scholar
• Roth, C., Rochlitz, C. and Kourilsky, P. (1994). Immune response against tumors. Adv Immunol, 57, 281–351.
   PubMed Web of Science ®Google Scholar
• Boon, T. (1992). Toward a genetc analysis of tumor rejection antigens. Adv. Cancer Res, 58, 177–210.
   PubMed Web of Science ®Google Scholar
• van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A. and Boon, T. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 254, 1643–1647.
   PubMed Web of Science ®Google Scholar
• Mandruzzato, S., Brasseur, F., Andry, G., Boon, T. and van der Bruggen, P. (1997). A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med, 186, 785–793.
   PubMed Web of Science ®Google Scholar
• Van Pel, A., van der Bruggen, P., Coulie, P. G., Brichard, V. G., Lethe, B., van den Eynde, B., Uyttenhove, C., Renauld, J. C. and Boon, T. (1995). Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev, 145, 229–250.
   PubMed Web of Science ®Google Scholar
• Robbins, P. F. and Kawakami, Y. (1996). Human tumor antigens recognized by T cells. Curr Opin Immunol, 5, 628–636.
   Web of Science ®Google Scholar
• Topalian, S. L., Rivoltini, L., Mancini, M., Markus, N. R., Robbins, P. F., Kawakami, Y. and Rosenberg, S. A. (1994). Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA, 91, 9461–9465.
   PubMed Web of Science ®Google Scholar
• Schwartz, R. H. (1996). Models of T cell anergy: Is there a common molecular mechanism? J. Exp. Med., 184, 1–8.
   PubMed Web of Science ®Google Scholar
• Lenschow, D. J., Walunas, T. L. and Bluestone, J. A. (1996). CD28/B7 system of T cell costimulation. Annu Rev Immunol, 14, 233–258.
   PubMed Web of Science ®Google Scholar
• Chen, L., Ashe, S., Brady, W. A., Hellström, I., Hellström, K. E., Ledbetter, J. A., McGowan, P. and Linsley, P. (1992). Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 71, 1093–1102.
   PubMed Web of Science ®Google Scholar
• Chen, L., McGowan, P., Ashe, S., Johnston, J. V., Li, Y., Hellström, I. and Hellströom, K. E. (1994). Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med, 179, 523–532.
   PubMed Web of Science ®Google Scholar
• Matzinger, P. (1994). Tolerance, danger, and the extended family. Annu Rev Immunol, 12, 991–1045.
   PubMed Web of Science ®Google Scholar
• Forni, G., Fujiwara, H., Martino, F., Hamaoka, T., Jemma, C., Caretto, P. and Giovarelli, M. (1988). Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy. Cancer Metastasis Rev, 4, 289–309.
   Web of Science ®Google Scholar
• Tepper, R. I., Pattengale, P. K. and Leder, P. (1989). Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell, 57, 503–512.
   PubMed Web of Science ®Google Scholar
• Simons, J. W. and Mikhak, B. (1998). Ex vivo gene therapy using cytokinetransduced tumor vaccines: molecular and clinical pharmacology. Sem Oncol, 25, 661–676.
   PubMed Web of Science ®Google Scholar
• Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. and Mulligan, R. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA, 90, 3539–3543.
   PubMed Web of Science ®Google Scholar
• Mulligan, R. C. (1991). Gene transfer and gene therapy.In: Lindsten, J., Petterson, U. eds. Etiology of Human Diseases at the DNA level. New York, N.Y. Raven Press, LtD; 143–189.
   Google Scholar
• Dranoff, G. and Mulligan, R. C. (1995). Gene Transfer as Cancer Therapy. Adv Immunol, 58, 417–454.
   PubMed Web of Science ®Google Scholar
• Adams, S. W. and Emerson, S. G. (1998). Gene Therapy for Leukemia and Lymphoma. Hematol/Oncol Clin North America, 12, 631–648.
   Web of Science ®Google Scholar
• Xu, H. J. (1997). Strategies for approaching retinoblastoma tumor suppressor gene therapy. Adv Pharmacol, 40, 369–397.
   PubMedGoogle Scholar
• Wills, K. N., Maneval, D. C., Menzel, P., Harris, M. P., Sutjipto, S., Vaillancourt, M. T., Huang, W. M., Johnson, D. E., Anderson, S. C., Wen, S. F., et al. (1994). Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther, 5, 1079–1088.
   PubMed Web of Science ®Google Scholar
• Hanania, E. G., Fu, S., Roninson, I., Zu, Z. and Deisseroth, A. B. (1995). Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit [see comments] [published erratum appears in Gene Ther 1995 Aug; 2(6): 433]. Gene Ther, 2, 279–284.
   Web of Science ®Google Scholar
• Deisseroth, A. B., Zu, Z., Claxton, D., Hanania, E. G., Fu, S., Ellerson, D., Goldberg, L., Thomas, M., Janicek, K., Anderson, W. F., Hester, J., Korbling, M., Durett, A., Moen, R., Berenson, R., Heimfeld, S., Hamer, J., Calvert, L., Tibbits, P., Talpaz, M., Kantarjian, H., Champlin, R. and Reading, C. (1994). Genetic marking shows that Ph+ cells present in autologous transplants of chonic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood, 83, 3068–3076.
   PubMed Web of Science ®Google Scholar
• Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, M., Rossini, S., Mavilio, F., Traversari, C. and Bordignon, C. (1997). HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia [see comments]. Science, 276, 1719–1724.
   PubMed Web of Science ®Google Scholar
• Crooke, S. T. (1997). Advances in understanding the pharmacological properties of antisense oligonu-cleotides. Adv Pharmacol, 40, 1–49.
   PubMedGoogle Scholar
• Irie, A., Kijima, H., Ohkawa, T., Bouffard, D. Y., Suzuki, T., Curcio, L. D., Holm, P. S., Sassani, A. and Scanlon, K. J. (1997). Anti-oncogene ribozymes for cancer gene therapy. Adv Pharmacol, 40, 207–257.
   PubMedGoogle Scholar
• Matulonis, U. A., Dosiou, C., Lamont, C., Freeman, G. J., Mauch, P., Nadler, L. M. and Griffin, J. D. (1995). Role of B7–1 in mediating an immune response to myeloid leukemia cells. Blood, 85, 2507–2515.
   PubMed Web of Science ®Google Scholar
• Matulonis, U., Dosiou, C., Freeman, G., Lamont, C., Mauch, P., Nadler, L. M. and Griffin, J. D. (1996). B7–1 Is Superior to B7–2 Costimulation in the Induction and Maintenance of T Cell-Mediated Antileukemia Immunity. J Immunol, 156, 1126–1131.
   PubMed Web of Science ®Google Scholar
• Dunussi-Joannopoulos, K., Weinstein, H. J., Nickerson, P. W., Strom, T. B., Burakoff, S. J., Croop, J. M. and Arceci, R. J. (1996). Irradiated B7–1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood, 87, 2938–2946.
   PubMed Web of Science ®Google Scholar
• Pardoll, D. M. (1993). Cancer vaccines. Immunol Today, 14, 310–316.
   PubMedGoogle Scholar
• Dunussi-Joannopoulos, K., Krenger, W., Weinstein, H. J., Ferrara, J. L. M. and Croop, J. M. (1997). CD8+ T-cells activated during the course of murine AML elicit therapeutic responses to late B7 vaccines after cytoreductive treatment. Blood, 89, 2915–2924.
   PubMed Web of Science ®Google Scholar
• Boyer, M. W., Vallera, D. A., Taylor, P. A., Gray, G. S., Katsanis, E., Gorden, K., Orchard, P. J. and Blazar, B. R. (1997). The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties. Blood, 89, 3477.
   PubMed Web of Science ®Google Scholar
• Hirano, N., Takahashi, T., Azuma, M., Okumura, K., Yazaki, Y., Yagita, H. and Hirai, H. (1997). Protective and therapeutic immunity against leukemia induced by irradiated B7–1 (CD80)-transduced leukemic cells. Hum Gene Ther, 8, 1375–1384.
   PubMed Web of Science ®Google Scholar
• Hirano, N., Takahashi, T., Azuma, M., Yazaki, Y., Yagita, H. and Hirai, H. (1997). Protective and therapeutic immunity against leukemia induced by irradiated B7–1 (CD80)-transduced leukemic cells. Leukemia, 11(Suppl 3), 577–581.
   PubMedGoogle Scholar
• Nakazaki, Y., Tani, K., Lin, Z. T., Sumimoto, H., Hibino, H., Tanabe, T., Wu, M. S., Izawa, K., Hase, H., Takahashi, S., Tojo, A., Azuma, M., Hamada, H., Mori, S. and Asano, S. (1998). Vaccine effect of granulocyte-macrophage colony-stimulating factor or CD80 gene-transduced murine hematopoietic tumor cells and their cooperative enhancement of antitumor immunity. Gene Ther, 5, 1355–1362.
   PubMed Web of Science ®Google Scholar
• Musiani, P., Modesti, A., Giovarelli, M., Cavallo, F., Colombo, M. P., Lollini, P. L. and Forni, G. (1997). Cytokines, tumour-cell death and immunogenicity: a question of choise. Immunol Today, 18, 32–37.
   PubMedGoogle Scholar
• Dunussi-Joannopoulos, K., Dranoff, G., Weinstein, H. J., Ferrara, J. L., Bierer, B. E. and Croop, J. M. (1998). Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccineselicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. Blood, 91, 222–230.
   PubMed Web of Science ®Google Scholar
• Steinman, R. M. (1991). The dendritic cell system and its role in immunogenicity. Annu Rev Immunol, 9, 271–296.
   PubMed Web of Science ®Google Scholar
• Dunussi-Joannopoulos, K., Runyon, K., Erikson, J., Schaub, R. G., Hawley, R. G. and Leonard, J. P. (1999). Vaccines with interleukin-12 (IL-12) transduced acute myeloid leukemia (AML) cells elicit very potent therapeutic and long-lasting protective immunity. Blood, 94, 4263–4273.
   PubMed Web of Science ®Google Scholar
• Trinchieri, G. (1998). Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol, 70, 83–243.
   PubMed Web of Science ®Google Scholar
• Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schreiber, R. D., Storkus, W. J., et al. (1994). Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol, 153, 1697–1706.
   PubMed Web of Science ®Google Scholar
• Brunda, M. J., Luistro, L., Hendrzak, J. A., Fountoulakis, M., Garotta, G. and Gately, M. K. (1995). Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother Emphasis Tumor Immunol, 17, 71–77.
   PubMed Web of Science ®Google Scholar
• Trinchieri, G. (1998). Proinflammatory and immunoregulatory functions of interleukin-12. Int Rev Immunol, 16, 365–396.
   PubMedGoogle Scholar
• Morecki, S., Lubina-Salomon, A., Slavin, S. and Nagler, A. (1998). Cytokine gene transduction into non-immunogeneic murine tumor cells. Cytokines Cell Mol Ther, 4, 87–94.
   PubMedGoogle Scholar